Loading…
Maker of medical imaging equipment — CT, MRI and PET scanners — competing with global imaging majors in China and abroad.
Maker of medical imaging equipment — CT, MRI and PET scanners — competing with global imaging majors in China and abroad.
Sells high-priced scanners to hospitals through public tenders and distributors, then earns service contracts and parts as the machines age. Most revenue is in China, with overseas sales growing.
In one line: China's GE HealthCare for imaging equipment.
Moat: narrow (scale, process know-how, installed base). Rare full-line domestic imaging-equipment maker gaining share against GE/Siemens/Philips in China.
Headquarters: Shanghai, China · Founded: 2011 · Employees: 8,703
Size Shanghai United Imaging Healthcare (688271.SS) is a China Health Care company (Medical Specialties) with a market value of $14.8B, the 158th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥119.80 on 6 Nov 2026.
Performance Over six months the shares gained 9.0%, against +38.5% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 27.3% over the last twelve months (peer median +4.5%); the operating margin is 9.3% (peer median 16.1%).
Valuation It trades at 46.9× forward earnings against a peer median of 20.9× (4th most expensive of 20).
Capital Return on invested capital runs 2.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥15.5B | CN¥13.8B | CN¥10.3B | CN¥11.4B | CN¥9.22B |
| Revenue growth | — | +34% | -10% | +23% | — |
| Gross profit | CN¥7.56B | CN¥6.26B | CN¥4.81B | CN¥5.19B | CN¥4.33B |
| EBITDA | n/a | CN¥2.19B | CN¥1.16B | CN¥1.73B | CN¥1.74B |
| Net income | CN¥1.78B | CN¥1.87B | CN¥1.26B | CN¥1.97B | CN¥1.66B |
| Free cash flow | -CN¥49.5M | CN¥675M | -CN¥2.46B | -CN¥799M | -CN¥20.0M |
| Capital expenditure | CN¥2.40B | CN¥2.09B | CN¥1.95B | CN¥1.08B | CN¥741M |
| Total debt | CN¥4.18B | CN¥1.67B | CN¥1.20B | CN¥474M | CN¥428M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai United Imaging Healthcare 688271.SS | $14.8B | +9% | +27% | 9% | 46.9× | n/a |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
| Siemens Healthineers SHL.DE | $55.9B | +31% | -1% | 15% | 18.9× | 9.0% |
| Koninklijke Philips PHIA.AS | $29.8B | +24% | -1% | 10% | 16.5× | 5.7% |
| Canon 7751.T | $28.4B | +18% | +4% | 10% | 12.2× | -0.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688271.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.6% | +13.9% | 9th lowest of 21 |
| 6-month return | +9.0% | +38.5% | 5th lowest of 21 |
| Distance from 52-week high | -22.7% | -12.0% | 2nd lowest of 21 |
| Revenue growth (TTM) | +27.3% | +4.5% | 4th highest of 21 |
| Operating margin | 9.3% | 16.1% | 6th lowest of 21 |
| Forward P/E | 46.9× | 20.9× | 4th most expensive of 20 |
| ROIC minus cost of capital | +2.3 pp | +0.8 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai United Imaging Healthcare 688271.SS | China | $14.8B | +9% | +27% | 9% | 46.9× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.4B | +49% | +35% | 10% | 137.4× | 52.8% | +33.5% |
| Baxter International BAX | United States | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% | -0.7% |
| Glaukos GKOS | United States | $13.3B | +68% | +47% | -9% | 155.4× | n/a | n/a |
| Smith & Nephew SN..L | United Kingdom | $13.1B | +5% | +2% | 17% | 14.4× | 11.1% | +5.6% |
| Revvity RVTY | United States | $17.3B | +54% | +5% | 15% | 26.7× | 27.3% | -5.5% |
| Penumbra PEN | United States | $12.6B | -1% | +17% | 12% | 54.9× | 30.1% | +20.2% |
| Coloplast A/S COLO-B.CO | Denmark | $17.7B | +26% | +4% | 25% | 19.9× | -1.8% | +8.3% |
| bioMerieux BIM.PA | France | $12.4B | +29% | -3% | 15% | 20.9× | 8.9% | +5.5% |
| Olympus 7733.T | Japan | $12.2B | +13% | +8% | 16% | 18.0× | -1.5% | +6.7% |
| Cooper Companies (The) COO | United States | $11.9B | +4% | +5% | 19% | 13.8× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.8B | -2% | +4% | 19% | 13.9× | 11.4% | +10.3% |
| Demant A/S DEMANT.CO | Denmark | $11.6B | +62% | +10% | 18% | 25.7× | 6.8% | +9.8% |
| Sartorius SRT.DE | Germany | $20.0B | +34% | +4% | 18% | 42.6× | 24.9% | +8.7% |
| Zimmer Biomet ZBH | United States | $20.1B | +29% | +7% | 16% | 12.0× | -1.4% | +3.2% |
| Guardant Health GH | United States | $20.2B | +58% | +43% | -40% | n/a | n/a | n/a |
| Sonova SOON.SW | Switzerland | $20.3B | +62% | -7% | 21% | 25.6× | 7.1% | +6.7% |
| Straumann STMN.SW | Switzerland | $20.4B | +25% | +2% | 21% | 31.9× | 15.2% | +12.8% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |